Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | DRD3 | P35462 | 3/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5596954 | 0.94 | DRD2 (0.38) | DRD2DRD3 | |
| SCHEMBL5410740 | 0.94 | NOS3 (0.37) | DRD2DRD3NOS3NOS1NOS2 | |
| SCHEMBL5597195 | 0.93 | DRD2 (0.39) | DRD2DRD3 | |
| SCHEMBL5596515 | 0.91 | DRD2 (0.39) | DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL5596712 | 0.90 | DRD2 (0.33) | DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL5596494 | 0.90 | DRD2 (0.36) | DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL5596947 | 0.89 | DRD2 (0.35) | DRD2DRD3 | |
| SCHEMBL5596645 | 0.89 | DRD2 (0.40) | DRD2DRD3ROCK2ROCK1 | |
| SCHEMBL5596886 | 0.88 | DRD3 (0.40) | DRD3 | |
| SCHEMBL5596849 | 0.88 | DRD2 (0.35) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1829876-A1 | NITROGENEOUS TRICYCLIC COMPOUND | Asahi Kasei Pharma Corporation (JP) | 2007-09-05 | — | — | EP | disclosed |
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | ASAHI KASEI PHARMA CORPORATION (JP) | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247266-A1 | Nitrogen-containing tricyclic compounds | MYO1B, CHRM1, MYL12A | DRD2 1473/4885DRD3 1028/4885CYP2D6 3698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.